Traductor

03 April 2012

Newly Found Protein Helps Cells Build Tissues


Brown University biologists have found a new molecule in fruit flies that is key to the information exchange needed to build wings properly. They have also uncovered evidence that an analogous protein may exist in people and may be associated with problems such as cleft lip, or premature ovarian failure.



As they work together to form body parts, cells in developing organisms communicate like workers at a construction site. The discovery of a new signaling molecule in flies by Brown University biologists not only helps explain how cells send many long-haul messages, but also provides new clues for researchers who study how human development goes awry, for instance in cases of cleft lip and palate.
For all the diversity of life, animal cells employ only a small set of proteins to send those jobsite signals that coordinate construction. For that reason, said Kristi Wharton, associate professor of molecular biology, cell biology and biochemistry, studying these proteins and pathways in fruit flies can allow biologists and physicians to explain how development and other cellular processes occur in a wide variety of creatures and tissues.
"We are interested in how the pattern of a hand forms or how the pattern of a wing forms," Wharton said. "How do cells know their position in a developing tissue?"
In humans a key family of the signaling molecules that convey such messages are bone morphogenic proteins (BMPs). In fruit flies the directly analagous proteins carry the name "glass-bottom boat" (Gbb), because a mutant form makes larvae appear clear instead of milky white. To date, the conventional wisdom has been that signaling comes from a fly form of BMP known as Gbb15.
"The thought for the longest time is that this smaller protein is the only product that is formed and important for signaling," Wharton said. "But we found another form of this signaling molecule that was not previously known."
Wharton and former postdoctoral fellow Takuya Akiyama introduce the new molecule, Gbb38, in the April 3 edition of the journal Science Signaling. Experiments showed that in tissues where it was abundant, particularly parts of the wing, Gbb38 proved responsible for more signaling activity than Gbb15, and appeared especially important for carrying long-haul signals.
Possible links to humans
In addition to the findings in flies, Akiyama found that mutations in the genes for making BMPs in humans that directly mirror the genetic code for making Gbb38 in flies, occur in people with cleft lip (with or without cleft palate), and the reproductive disorders premature ovarian failure and persistent Mullerian duct syndrome. In other words, a mutation that interrupts Gbb38 production in flies, is analogous to the mutations associated with developmental disorders in different tissues in people.
The genetic analysis doesn't prove that mutations that hinder the production of an analogous signaling protein in humans would be the cause of those diseases, Wharton said. In fact, a longer-form BMP like Gbb38 has yet to be discovered in people. But the new discovery at least suggests the need for research to investigate that link, perhaps first in mice, she said.
Another potential benefit of the finding, she said, is that finding a Gbb38 analogue in humans could improve the current use of BMPs as therapeutics for bone repair, spinal fusions, and reconstruction of maxillofacial bone defects.
"If large forms of human BMPs are indeed present, which is suggested by the three human mutations, then they could be a very useful alternatives to the short BMPs because the large forms are more active in terms of signaling and have different properties in vivo," Wharton said.
Discovery on the wing
In the new paper, aided by an antibody provided by second author Guillermo Marques of the University of Alabama, Akiyama and Wharton were able to discover Gbb38 because they first asked what happened when they interrupted the creation of Gbb15. When they did that, by mutating the genetic instructions that tell enzymes where to cut Gbb15 out of a longer protein, they noticed that signaling activity was only mildly reduced instead of completely gone as conventional wisdom would have predicted.
Further research showed that there was another place where enzymes could cut to make a protein. Cutting at that spot yielded the longer Gbb38 protein. When they interrupted that cleavage in flies, the researchers found that signaling was significantly hindered. A total reduction in signaling came from interrupting both Gbb15 and Gbb38.
In local areas of wing tissue, meanwhile, Akiyama found that interrupting Gbb15 had consequences for signaling only among neighboring cells. Interrupting Gbb38, meanwhile, left local signaling intact, but created problems significantly farther away.
"The small protein doesn't move very far across the tissue," Wharton said. "But we found the large protein has a very long range. That may provide one answer to the long-standing question about what regulates the range of these signaling molecules."
The view for developmental biologists, therefore, may indeed be clearer in a larger glass-bottom boat.
The National Institute of General Medical Sciences funded the research.

**Published in "SCIENCE DAiLY"

USP y Quirón empujan la sanidad privada hacia la concentración en España



Fachada de la Clínica Quirón de Barcelona. / TONY GARRIGA
Esta operación, que acaba de recibir el visto bueno de la Comisión Nacional de la Competencia, como indicaron desde esta institución, confirma la tendencia a la agrupación en el sector hospitalario privado, “muy fragmentado y que contrasta con la concentración del segmento de los seguros privados”, como apunta Ignacio Riesgo, responsable de sanidad de la consultora PricewaterhouseCoopers (PwC). Por ello, aún hay margen para que se produzcan más movimientos similares. De hecho, existía otro gran proceso en marcha: la compra de Ribera Salud —accionista de seis hospitales de gestión privada— por parte del que era el primer grupo hospitalario privado de España, Capio, una negociación que se ha atascado en la recta final.
Fuente: PricewaterhouseCoopers. / EL PAÍS
 En la trastienda de estas operaciones se encuentran varios factores. Por un lado, la asimetría que se da en el mercado español entre la concentración del sector de los seguros y la atomización, no solo de los hospitales, sino también de la provisión de servicios sanitarios privados (laboratorios de análisis, servicios de radiología). Ejemplo de ello es que mientras los cuatro primeros grupos de aseguradoras (Grupo Caixa, Sanitas, Asisa y Mapfre) suman el 60% de las primas, las cuatro primeras redes hospitalarias privadas (Capio, Adeslas, USP y Quirón) apenas copan el 24%. Más aún, los siete grandes grupos de hospitales tan solo alcanzan el 32,8% del mercado.
De este desequilibrio se deriva una situación de dominio de los seguros, que les permite negociar en una situación de fuerza con los hospitales privados. Incluso con los centros pertenecientes a grupos, las aseguradoras negocian las condiciones de colaboración individualmente con cada hospital. “No existe ninguna red hospitalaria privada con la suficiente fuerza como para negociar a nivel colectivo”, comenta Riesgo. De ahí las estrategias hospitalarias de reagrupamiento. El informe que anualmente elabora PwC a modo de radiografía del sector sanitario en España, 10 temas candentes de la sanidad española para 2011, ya advertía sobre esta cuestión: “Se dará un salto en el proceso de concentración del sector sanitario privado”.
“Vamos hacia un proceso de unión como sucedió hace unos
años con los hoteles"
El protagonismo que están adquiriendo las compañías de capital riesgo en el sector de la sanidad privada, que se han convertido en las principales animadoras de las operaciones, es otro de los aspectos que explica la tendencia a la agrupación de hospitales privados. Doughty Hanson adquirió en febrero USP Hospitales por 355 millones de euros a sus anteriores propietarios, el Bank of Scotland y Barclays. Tras tomar el control del tercer grupo hospitalario español, la firma británica procedió a la fusión con Hospitales Quirón aprovechando la salida del socio minoritario, el grupo portugués José de Mello, que compartía el accionariado con la familia Cordón. Ni Doughty Hanson ni Quirón han querido dar detalles de la operación.
Gracias al acuerdo entre ambas entidades, al que la Comisión Nacional de la Competencia no ha puesto ninguna traba, el grupo resultante suma una veintena de hospitales y unas 2.000 camas, además de otra veintena de clínicas auxiliares y tres unidades de reproducción asistida. Su volumen de ingresos supera por décimas a los 8,8% de cuota de mercado hospitalario privado (con datos de 2010) de Capio, el anterior líder del sector. También en camas, superará a las 1.584 de Capio.

Operación atascada

Otro proceso que iba en la misma dirección de sumar recursos es la compra de Ribera Salud —la compañía valenciana principal impulsora de la modalidad de gestión privada de centros públicos— por parte de Capio, controlado por el fondo de capital CVC Capital Partners, británico con sede en Luxemburgo. La idea era formar el mayor grupo sanitario privado enfocado, en este caso, a la gestión de centros de titularidad pública y la prestación de servicios sanitarios a la Administración.
La venta, que rondaba los 110 millones de euros, se encuentra en punto muerto debido, según fuentes próximas a la operación, a las garantías de cobro exigidas por Capio, ya que el cliente principal de Ribera Salud es la Administración valenciana, acosada por las deudas y los impagos. Este retraso corre a favor de la compañía valenciana de Atitlán. El fondo de inversión que gestiona Roberto Centeno, el yerno de Juan Roig (presidente y propietario de Mercadona) ha mostrado en distintas ocasiones su interés por hacerse con las riendas de Ribera Salud.
“El proceso de concentración hospitalario no ha hecho más que empezar”, insiste Ignacio Riesgo. “Vamos hacia un proceso de unión como sucedió hace unos años con los hoteles, que se han agrupado todos en torno a grandes grupos”.

*Publicado en "EL PAIS"

Ovastacin Cuts Off Sperm Binding



Researchers have described how a secreted protease helps egg cells avoid being fertilized by more than one sperm.

  • Because polyspermy disrupts embryonic development, oocytes take several steps to ensure they only fuse with a single sperm. One key step is to prevent additional sperm from binding to the surface of an already-fertilized egg, a blockade that involves the release of secretory granules and cleavage of the glycoprotein ZP2, a component of the zona pellucida matrix that surrounds eggs. ZP2 is cleaved upstream of two acidic amino acids, a cleavage site recognized by the astacin family of metalloendoproteases. Burkart et al. therefore investigated the function of ovastacin, an astacin family member expressed in oocytes.
Ovastacin localized to cortical granules that were exocytosed after fertilization, and recombinant ovastacin cleaved ZP2 when added to zonae pellucidae. Mice lacking ovastacin failed to cleave ZP2 after fertilization, allowing sperm to continue to bind to the surface of early embryos. Ovastacin-null female mice had slightly fewer offspring than wild-type animals but otherwise appeared normal.
The researchers found that ovastacin targeted several sites in ZP2's N terminus. Senior author Jurrien Dean now wants to investigate how this proteolysis blocks sperm binding, a critical question because the molecular interactions between sperm and egg cells remain unknown. He also wants to examine how ovastacin is packaged into oocyte cortical granules and to identify other components of these secretory organelles.

**Published in "SCIENCE DAILY"

La incidencia de cáncer de piel aumenta entre los jóvenes


Los propios autores del estudio se han sorprendido con los resultados. Lejos de reducirse, la tasa de cáncer de piel aumenta, especialmente entre quienes aún no han cumplido los 40 años. Así lo revelan los datos de un trabajo realizado en la Clínica Mayo (Rochester, Minnesota, EEUU), de los que también se concluye que las mujeres son las más 'castigadas' por esta enfermedad.
En línea con lo que otras investigaciones apuntaban, "ya imaginábamos que encontraríamos un incremento de casos, pero no que superarían a los que indica el Instituto Nacional de Cáncer de EEUU (NCI, en sus siglas en inglés)", argumentan los responsables del nuevo trabajo que acaba de publicar la revista 'Mayo Clinic Proceedings'. En particular, les ha llamado la atención la importante incidencia en las mujeres entre los 20 y los 30 años.
Después de revisar una base de datos de Olmsted (Minnesota, EEUU) con los primeros diagnósticos de melanoma en pacientes de 18 a 39 años entre 1970 y 2009, el principal líder de la investigación, Jerry Brewer y su equipo, observaron que la incidencia de melanoma aumentaba ocho veces entre las mujeres y cuatro veces entre los hombres.
Un panorama muy similar al español. "De hecho, en la Academia Andaluza de Dermatología se ha hecho un estudio sobre el cáncer de piel en el que se concluye no sólo que no se ha detenido la incidencia (como esperábamos a principios de los '90 con las campañas de prevención) sino que ha aumentado, sobre todo en los jóvenes y más en mujeres", argumenta Julián Conejo-Mir, jefe de Servicio de Dermatología del Hospital Universitario Virgen del Rocío de Sevilla.

Donde no da el sol

"Algo (además del sol como principal causa) está pasando", remarca el especialista español. Ya hay estudios, continúa, que señalan como culpables a las "mutaciones en los genes BRAF, NRAS y KIT". Esto explicaría los casos donde el cáncer de piel aparece en "localizaciones donde no da el sol, como los genitales, detrás de la oreja, etc". Lo que no se sabe es "qué es lo que está haciendo que estas mutaciones aumenten y en esta línea se está investigando en todo el mundo". Y añade: "Llevamos 30 años haciendo campañas de prevención solar y la incidencia del cáncer de piel sigue aumentando, algo se nos escapa".
Los investigadores del estudio estadounidense señalan las cabinas de bronceado como clave en el incremento de esta enfermedad, sobre todo en mujeres. "Un reciente estudio decía que los usuarios de estas camas tienen un 74% más de riesgo de desarrollar melanoma y sabemos que esta práctica les gusta más a ellas que a ellos". Sin embargo, a pesar de la abundante información que se ofrece a la sociedad al respecto, "siguen acudiendo a estas cabinas".
Dados los resultados de "nuestro estudio, se deberían desarrollar intervenciones que consigan reducir factores de riesgo de este tipo, que continúen subrayando los efectos carcinógenos de las camas de bronceado y recuerden la importancia de someterse a revisiones dermatológicas, sobre todo cuando se noten cambios y lesiones en la piel", concluye Bewer.
Precisamente este año, uno de los objetivos de la próxima campaña de cáncer de piel de la Academia Española de Dermatología y Venereología (AEDV) "serán las cabinas de rayos UVA", adelanta el doctor Conejo-Mir.

**Publicado en "EL MUNDO"
anapixel

New Immune Defense Enzyme Discovered



Neutrophil granulocytes comprise important defences for the immune system. When pathogenic bacteria penetrate the body, they are the first on the scene to mobilise other immune cells via signal molecules, thereby containing the risk. To this end, they release serine proteases – enzymes that cut up other proteins to activate signal molecules. Scientists at the Max Planck Institute of Neurobiology in Martinsried have now discovered a new serine protease: neutrophil serine protease 4, or NSP4. This enzyme could provide a new target for the treatment of diseases that involve an overactive immune system, such as rheumatoid arthritis.
The functioning of the immune system is based on the complex interplay of the most diverse cells and mediators. For example, neutrophil granulocytes (a group of specialized white blood cells) react to bacteria by releasing substances called serine proteases. These enzymes are able to activate signal molecules, such as the chemokines, by cleaving them at a specific position on the molecule. The active signal molecules then guide other immune cells to the focus of inflammation in order to destroy the pathogens.
A research team led by Dieter Jenne at the Max Planck Institute of Neurobiology in Martinsried has come across a previously unknown protease in humans: neutrophil serine protease 4, or NSP4. "The special thing about this enzyme is that it cuts proteins that have the amino acid arginine at a particular point", says Dieter Jenne, research group leader at the Martinsried-based Institute. "This is where NSP4 differs from the other three known neutrophil serine proteases, which are similar in molecular structure, but have a different recognition motif." The scientists may be able to harness this difference to develop an active substance that specifically inhibits NSP4, thereby reducing the immune reaction.
However, serine protease activity comes at a cost. The enzymes not only heal inflammations, but sometimes cause them in the first place. If too many immune cells are activated, they can use their arsenal of aggressive chemical weapons against the body's own tissues. A number of chronic inflammatory diseases are based on precisely this effect. As a result, scientists are searching for substances that can block the neutrophil proteases. To date, however, none of the substances tested have been developed into effective drugs.
"So far, we don't know the identity of the NSP4 substrate, but we assume they must be signal molecules", says Dieter Jenne. Activated chemokines can recruit a vast number of neutrophils, and their sheer quantity alone is enough to cause tissue damage. "Proteases sometimes act as accelerants and can even trigger a chronic inflammation quite independently of bacterial intruders. If we dampened down the defences, we could counteract this effect", explains the scientist.
In terms of evolutionary history, NSP4 is the oldest of the four known neutrophil serine proteases. Using gene sequences, scientists have shown that the enzyme has hardly changed through hundreds of millions of years of evolution from bony fish to humans. "That would indicate that NSP4 regulates a fundamental process", says Dieter Jenne.
The fact that the enzyme remained undiscovered until now is because it occurs at a much lower concentration than the other three proteases. The Max Planck scientists came across it while searching the human genome for genes that encode serine proteases. In the process, they noticed a previously unknown gene sequence. Natascha C. Perera, a member of the Martinsried research group and lead author of the study, managed to produce and examine the enzyme in its active, folded state.
If they are to establish NSP4 in the future as a possible target protein for anti-inflammatory drugs, the scientists must now examine its function in living organisms and discover whether blocking the enzyme has adverse effects. The scientists are working with the company Novartis to answer these questions in laboratory mice. "NSP4 inhibitors could be used in diseases like chronic arthritis or inflammatory skin diseases", says Dieter Jenne, "but first we have to test the long-term effects of these substances."

**Published in "SCIENCE DAILY"

Un estudio arroja dudas sobre la utilidad de los test genómicos


Al ritmo que avanza la técnica, es más que probable que dentro de pocos años (cada vez menos), cualquiera pueda secuenciar su propio genoma por unos pocos euros. Sin embargo, la utilidad real de estos test está en entredicho a juzgar por el último análisis que acaba de publicar la revista 'Science Traslational Medicine'.
Más allá del capricho de unos pocos, o de algunas experiencias en el terreno experimental, el análisis del genoma completo de un individuo está aún lejos de convertirse en una herramienta útil en la práctica clínica diaria.
Así lo advierten Bert Vogelstein y su equipo, del Instituto Howard Hughes (en Baltimore, EEUU), después de analizar a miles de gemelos cuyos datos están almacenados en bases de datos de Suecia, Dinamarca, Finlandia, Noruega y EEUU. "Gemelos idénticos comparten un genoma idéntico y, por tanto, los mismos factores genéticos de riesgo", explican los investigadores, que utilizaron un modelo matemático para predecir las probabilidades de cada par de individuos de padecer una lista de 24 patologías (cáncer, ictus, patologías cardiovasculares, neurológicas, autoinmunes...) en comparación con el riesgo medio de la población general.
Con este modelo predictivo, diseñado por el hijo del propio Vogelstein, la mayoría de sujetos obtuvo un resultado negativo para 23 de las 24 enfermedades; lo que no quiere decir, ni mucho menos, que estén cien por cien libres de riesgo de padecer alguna de ellas a lo largo de su vida.
"Por ejemplo, sólo un 2% de las mujeres que se someten a un análisis del genoma completo recibirá un resultado positivo para un posible cáncer de ovario a lo largo de su vida", explica otro de los firmantes, Kenneth Kinzler. Eso no quiere decir que el 98% de las mujeres tenga garantías de que no va a padecer la enfermedad a lo largo de su vida.
"Los test genómicos no son un sustituto adecuado de las actuales estrategias de prevención", advierte Vogelstein. De momento, pues, las pruebas de diagnóstico precoz y las recomendaciones de prevención, como no fumar, siguen siendo la norma de oro para reducir el riesgo de numerosas enfermedades.
A su juicio, algunos individuos podrían pensar erróneamente que no padecerán ciertas enfermedades si su genoma no advierte de ellas; lo que resta valor informativo a dichos análisis. "No se puede concluir que dichos test sean útiles o inútiles en un sentido absoluto; su utilidad dependerá de sus resultados, de cada individuo, de sus perspectivas... Y reconocer estas limitaciones será de gran utilidad para la industria, las compañías de seguros, las autoridades sanitarias y los consumidores", rematan.

**Publicado en "EL MUNDO"

Caloric Moderation Can Reverse Link Between Low Birth Weight and Obesity, Early Study Indicates


Babies who are born small have a tendency to put on weight during childhood and adolescence if allowed free access to calories. However, a new animal model study at UCLA found when small babies were placed on a diet of moderately regulated calories during infancy, the propensity of becoming obese decreased.


Because this is an early study, UCLA researchers do not recommend that mothers of low-birth weight infants start restricting their child's nutrition and suggest they consult with their child's pediatrician regarding any feeding questions.
Previous studies have shown that growth restriction before birth may cause lasting changes of genes in certain insulin-sensitive organs like the pancreas, liver and skeletal muscle. Before birth, these changes may help the malnourished fetus use all available nutrients. However, after birth these changes may contribute to health problems such as obesity and diabetes.
"This study shows that if we match the level of caloric consumption after birth to the same level that the growth-restricted baby received in the womb, it results in a lean body type. However, if there is a mismatch where the baby is growth-restricted at birth but exposed to plenty of calories after birth, then that leads to obesity," said the lead author, Dr. Sherin Devaskar, professor of pediatrics and executive chair of the department of pediatrics at Mattel Children's Hospital UCLA. "While many trials that include exercise and various drug therapies have tried to reverse the tendency of low birth weight babies becoming obese, we have shown that a dietary intervention during early life can have long lasting effects into childhood, adolescence and adult life."
The study appears in the June issue of the journal Diabetes and is currently available online.
About 10 percent of babies in the United States are born small, defined as less than the 10th percentile by weight for a given gestation period, said the study's first author, Dr. Meena Garg, professor of pediatrics and a neonatologist and medical director of the neonatal intensive care unit at Mattel Children's Hospital UCLA. She added that some organizations define low birth weight as less than 2,500 grams or 5 pounds, 5 ounces at term.
Low birth weight can be caused by malnutrition due to a mother's homelessness or hunger or her desire not to gain too much weight during pregnancy. Additional causes include illness or infection, a reduction in placental blood, smoking or use of alcohol or drugs during pregnancy.
To conduct the study, researchers used rodent animal models and simulated a reduced calorie scenario during pregnancy. The results showed that low-birth weight offspring exposed to moderately tempered caloric intake during infancy and childhood resulted in lean and physically active adults related to high energy expenditure, as opposed to unrestricted intake of calories, which resulted in inactive and obese adults due to reduced energy expenditure. The authors concluded that early life dietary interventions have far reaching effects on the adult state.
Future studies will follow this study over the stages of aging to see if early regulation of calorie intake reverses diabetes and obesity while aging.
"This is an early pre-clinical trial that first needs to be tested in clinical trials before any form of guidelines can be developed," Devaskar said. "More importantly, we must make sure that control of caloric intake during infancy and childhood does not have any unintended side effects before taking on clinical trials. More research is required to ensure that these metabolic advantages will persist later in life."

**Published in "SCIENCE DAILY"

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud